The surge in popularity of GLP-1 receptor agonists – medications like Ozempic and Wegovy initially developed for Type 2 diabetes, now widely used for weight loss – has understandably focused on their dramatic clinical effects. But as millions begin and maintain treatment, a crucial question emerges: what are the long-term consequences beyond weight and blood sugar? Preliminary data presented this week at the American Academy of Orthopaedic Surgeons’ annual meeting suggests a potential link between GLP-1 use and a modestly increased risk of osteoporosis and gout, prompting a necessary recalibration of how we understand the overall risk-benefit profile of these drugs. It’s a conversation moving beyond celebratory headlines about weight loss to a more nuanced assessment of metabolic shifts and skeletal health.
John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, initiated this line of inquiry after observing a concerning trend in his practice. He noticed some patients experienced surprisingly severe tendon tears following relatively minor injuries, leading him to investigate whether GLP-1 medications might be impacting connective and bone tissue more broadly. This wasn’t a search for a problem, but a response to clinical observations – a hallmark of good medical investigation. His team then analyzed five years of medical records, encompassing over 146,000 adults diagnosed with both obesity and Type 2 diabetes, comparing outcomes for those taking GLP-1 drugs versus those who weren’t. The study, while not yet published in a peer-reviewed journal, revealed that approximately 4% of GLP-1 users developed osteoporosis, compared to just over 3% of non-users – a roughly 30% increase in risk. The incidence of osteomalacia, a softening of the bones, also appeared to double in the GLP-1 group.
It’s vital to clarify what these findings do and do not demonstrate. Headlines proclaiming a direct causal link between GLP-1s and osteoporosis are premature. This was an observational study, meaning researchers identified a correlation, but cannot definitively prove that the drugs caused the increased risk. As Horneff himself emphasizes, the data showed a “nearly doubling of the risk of having some sort of bone mineral density issue at five years,” but that’s a relative increase from a baseline risk. Furthermore, the records lacked specifics on which GLP-1 medication each patient received – whether it was semaglutide (Ozempic/Wegovy) or liraglutide (Victoza/Saxenda) – hindering a more granular analysis. The observed increase in gout rates, around 12%, similarly requires cautious interpretation. While statistically significant, the absolute difference between groups (7.4% vs. 6.6%) is small, and the study couldn’t account for dietary factors known to influence uric acid levels.
This article draws on reporting from NBC News.
The underlying mechanism driving these potential associations is likely multifactorial. Clifford Rosen, a professor of medicine at Tufts University, points to the well-established link between weight loss and bone loss. “Weight loss does cause bone loss,” he stated, framing the question as whether the bone changes observed with GLP-1s represent a normal skeletal adaptation to reduced load or a more accelerated, problematic loss of bone density. Horneff proposes two key pathways: nutritional deficiencies stemming from reduced food intake, and the physiological impact of rapid weight loss itself. He draws a parallel to astronauts in zero gravity, whose bones weaken without the constant stress of supporting their weight. This analogy highlights the importance of mechanical loading for bone health, suggesting that a rapidly shrinking frame may not adequately stimulate bone formation.
However, the narrative isn’t solely one of risk. Susan Spratt, an endocrinologist at Duke Health, notes that some studies suggest musculoskeletal benefits with GLP-1s, and many patients report improvements in joint pain alongside weight loss. This underscores a critical distinction: joint health and bone density are not synonymous. Moreover, Christopher McGowan, a gastroenterologist specializing in weight loss, emphasizes the mitigating role of lifestyle interventions. His data suggest that combining GLP-1s with structured exercise can largely offset bone density loss. This isn’t a signal to abandon these medications, but a call for a more holistic approach to obesity treatment, integrating nutritional guidance, exercise programs, and proactive bone health monitoring. The FDA already acknowledges a potential increased fracture risk in older adults and women using semaglutide, a detail often overlooked in initial enthusiasm.
Looking ahead, the most pressing research need is prospective, controlled trials designed to specifically assess the long-term impact of GLP-1s on bone mineral density and fracture risk. These studies should meticulously track dietary intake, exercise habits, and vitamin D/calcium supplementation to disentangle the contributions of each factor. Crucially, researchers need to differentiate between the effects of various GLP-1 medications, as their pharmacological profiles may differ. Beyond bone health, further investigation into the long-term effects on muscle mass and connective tissue is warranted. For patients currently on GLP-1s, the immediate takeaway isn’t alarm, but awareness. Individuals should discuss their bone health with their physicians, particularly if they have pre-existing risk factors for osteoporosis, and consider incorporating weight-bearing exercise and adequate nutrient intake into their routines. The question now isn’t if these medications are effective for weight loss, but how we can optimize their use to minimize potential long-term skeletal consequences. Will future guidelines recommend routine bone density screenings for patients on GLP-1s, and if so, at what intervals? That’s a scenario healthcare providers and patients alike should be prepared to address.
